Cytek BioSciences Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 1.15
Dividend & YieldN/A$ (N/A)
Beta N/A
Market capitalization 1.63B
Operating cash flow -12.98M
ESG Scores unknown

Company description

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Sector: Healthcare - Industry: Medical Devices

Financial data

Financial Statements

Cashflow Statement 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -233k 2.32M 9.76M
Total Cashflows From Investing Activities -973k -1.55M -20.99M
Net Borrowings 2.77M 2.77M -2.77M
Total Cash From Financing Activities 93k 122.61M 213.56M
Change To Operating Activities 28.62M -4.49M 1.03M
Issuance Of Stock 93k 169k 216.33M
Net Income -16.83M 19.41M 3.05M
Change In Cash -14.66M 135.63M 198.5M
Effect Of Exchange Rate -33k -587k 1.3M
Total Cash From Operating Activities -13.75M 15.16M 4.63M
Depreciation 309k 603k 1.24M
Change To Account Receivables -12.61M 334k -12.37M
Other Cashflows From Financing Activities
Change To Netincome 1.61M 2.68M 8.98M
Capital Expenditures -973k -1.55M -4.36M

Income Statement 2019-12-31 2020-12-31 2021-12-31
Research Development 8.93M 13.69M 24.44M
Income Before Tax -16.29M 14.43M 5.94M
Net Income -16.83M 19.41M 3.05M
Selling General Administrative 16.98M 24.36M 45.55M
Gross Profit 28.67M 51.71M 79.14M
Ebit 2.76M 13.66M 9.16M
Operating Income 2.76M 13.66M 9.16M
Interest Expense -1k -333k -1.74M
Income Tax Expense 533k -4.98M 2.91M
Total Revenue 57.88M 92.84M 127.95M
Cost Of Revenue 29.21M 41.13M 48.81M
Total Other Income ExpenseNet -19.06M 771k -3.22M
Net Income From Continuing Ops -16.83M 19.41M 3.03M
Net Income Applicable To Common Shares -16.83M 3.22M 52k

Balance Sheet Statement 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 37.41M 41.69M 57.92M
Total Stockholder Equity -41.7M -16.03M 405.04M
Other Current Liabilities 12.52M 12.18M 15.25M
Total Assets 70.36M 219.98M 463.31M
Common Stock 21k 23k 126k
Other Current Assets 419k 1.33M 708k
Retained Earnings -42.02M -22.61M -19.61M
Treasury Stock -147k 65k 897k
Cash 30.12M 165.23M 364.62M
Total Current Liabilities 21.04M 26.54M 33.18M
Other Stockholder Equity -147k 65k 897k
Property, Plant, and Equipment 1.04M 2.14M 5.85M
Total Current Assets 67.77M 208.62M 431.73M
Net Tangible Assets -42.44M -16.78M 390.16M
Net Receivables 17.75M 18.1M 29.63M
Accounts Payable 2.34M 2.94M 3.03M


Insider Transactions

Here are the insider transactions of stock shares related to Cytek BioSciences Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
JEANMONOD PATRICKSale at price 14.30 per share.D2022-11-25Chief Financial Officer3.5k
YAN MINGSale at price 14.66 per share.D2022-11-21Chief Technology Officer20k
POIRSON ALLEND2022-11-18Officer790
BARNETT VALERIED2022-11-18General Counsel2.02k
JIANG WENBIND2022-11-18Chief Executive Officer6.76k
YAN MINGD2022-11-18Chief Technology Officer1.98k
JEANMONOD PATRICKD2022-11-18Chief Financial Officer1.75k
BALL JACKSale at price 14.69 per share.D2022-11-14Director16k
BALL JACKConversion of Exercise of derivative security at price 0.40 per share.D2022-11-14Director16k
JIANG WENBINSale at price 14.76 per share.D2022-11-07Chief Executive Officer20k
JEANMONOD PATRICKSale at price 15.16 per share.D2022-10-24Chief Financial Officer3.5k
YAN MINGSale at price 14.42 per share.D2022-10-19Chief Technology Officer20k
JIANG WENBINSale at price 14.79 per share.D2022-10-07Chief Executive Officer20k
JEANMONOD PATRICKSale at price 12.63 per share.D2022-09-26Chief Financial Officer3.5k
YAN MINGSale at price 12.42 per share.D2022-09-19Chief Technology Officer20k
JIANG WENBINSale at price 12.89 per share.D2022-09-07Chief Executive Officer20k
JEANMONOD PATRICKSale at price 13.45 per share.D2022-08-24Chief Financial Officer3.5k
YAN MINGSale at price 13.62 per share.D2022-08-19Chief Technology Officer20k
POIRSON ALLEND2022-08-18Officer790
BARNETT VALERIED2022-08-18General Counsel2.02k
JIANG WENBIND2022-08-18Chief Executive Officer6.76k
YAN MINGD2022-08-18Chief Technology Officer1.98k
JEANMONOD PATRICKD2022-08-18Chief Financial Officer1.75k
JIANG WENBINSale at price 15.09 per share.D2022-08-08Chief Executive Officer20k
JEANMONOD PATRICKSale at price 12.80 per share.D2022-08-01Chief Financial Officer3.5k
YAN MINGSale at price 11.83 per share.D2022-07-19Chief Technology Officer20k
JIANG WENBINSale at price 11.19 per share.D2022-07-07Chief Executive Officer20k
YAN MINGSale at price 10.06 per share.D2022-06-21Chief Technology Officer20k
JIANG WENBINSale at price 10.75 per share.D2022-06-07Chief Executive Officer20k
YAN MINGSale at price 9.92 per share.D2022-05-19Chief Technology Officer20k
POIRSON ALLEND2022-05-18Officer1.05k
BARNETT VALERIED2022-05-18General Counsel2.69k
JIANG WENBIND2022-05-18Chief Executive Officer9.01k
YAN MINGD2022-05-18Chief Technology Officer2.64k
JEANMONOD PATRICKD2022-05-18Chief Financial Officer2.34k
JIANG WENBINSale at price 8.01 per share.D2022-05-09Chief Executive Officer20k
YAN MINGSale at price 10.34 per share.D2022-04-19Chief Technology Officer20k
JIANG WENBINSale at price 10.54 per share.D2022-04-07Chief Executive Officer20k
YAN MINGSale at price 11.64 per share.D2022-03-21Chief Technology Officer20k
RA CAPITAL MANAGEMENT, L.P.Purchase at price 12.27 - 12.35 per share.I2022-03-15Beneficial Owner of more than 10% of a Class of Security583.87k
RA CAPITAL MANAGEMENT, L.P.Purchase at price 12.77 - 12.99 per share.I2022-03-11Unknown634.64k
RA CAPITAL MANAGEMENT, L.P.Purchase at price 12.61 - 12.99 per share.I2022-03-08Beneficial Owner of more than 10% of a Class of Security647.26k
JIANG WENBINSale at price 12.58 - 13.79 per share.D2022-03-07Chief Executive Officer20k
YAN MINGConversion of Exercise of derivative security at price 0.25 - 0.92 per share.D2022-03-07Chief Technology Officer73.01k
BARNETT VALERIEConversion of Exercise of derivative security at price 4.71 per share.D2022-03-04General Counsel10.5k
JIANG WENBINConversion of Exercise of derivative security at price 0.25 per share.D2022-03-04Chief Executive Officer66.67k
RA CAPITAL MANAGEMENT, L.P.Purchase at price 12.89 - 12.98 per share.I2022-03-02Unknown441.87k
RA CAPITAL MANAGEMENT, L.P.Purchase at price 12.99 - 13.41 per share.I2022-02-25Unknown420.38k
RA CAPITAL MANAGEMENT, L.P.Purchase at price 13.46 - 14.78 per share.I2022-02-22Beneficial Owner of more than 10% of a Class of Security547.38k
YAN MINGSale at price 13.44 per share.D2022-02-22Chief Technology Officer20k
RA CAPITAL MANAGEMENT, L.P.Purchase at price 14.72 - 14.99 per share.I2022-02-16Beneficial Owner of more than 10% of a Class of Security498.63k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Cytek BioSciences Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Cytek BioSciences Inc

Here is the result of two systematic investment strategies applied to Cytek BioSciences Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Cytek BioSciences Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Cytek BioSciences Inc:

Cytek BioSciences Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -2.48% on the backtest period.

Performance at glance

Performance

-2.48 %

Latent gain

-6.0 $

Invested capital

242.3 $

Annualized return

-7.75 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Cytek BioSciences Inc

This is the result of two momentum investment strategies applied to Cytek BioSciences Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Cytek BioSciences Inc

The following chart shows all the entries opened by the momentum investment system on Cytek BioSciences Inc:

Cytek BioSciences Inc momentum entries
  • The first momentum investment strategy would give 0.94% of return on Cytek BioSciences Inc. That represents 4.62$ of latent gain with 491.61$ of employed capital.
  • The second momentum investment strategy would give 0% of return on Cytek BioSciences Inc. That represents 0.0$ of latent gain with 0.0$ of employed capital.
Performance at glance (1Q Momentum)

Performance

0.94 %

Latent gain

4.62 $

Invested capital

491.61 $

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

-0.0 %

Momentum equity curve on Cytek BioSciences Inc

The following chart shows the equity curve of the two momentum strategies applied to Cytek BioSciences Inc:

Cytek BioSciences Inc momentum equity

Note: the dividends potentially given by Cytek BioSciences Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Cytek BioSciences Inc

The following chart shows the employed capital evolution of the two momentum strategies on Cytek BioSciences Inc since the beginning:

Cytek BioSciences Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Cytek BioSciences Inc

Buy the dip entry openings on Cytek BioSciences Inc

Cytek BioSciences Inc

The performance achieved by the robo-advisor on Cytek BioSciences Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Cytek BioSciences Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Cytek BioSciences Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

-0.0 %

Equity curve of the strategy applied to Cytek BioSciences Inc

The following chart shows the result of the investment strategy applied to Cytek BioSciences Inc:

Cytek BioSciences Inc

Note: the dividends potentially given by Cytek BioSciences Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Cytek BioSciences Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Cytek BioSciences Inc:

Cytek BioSciences Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Cytek BioSciences Inc

In this section, I will compare the three previous investment strategies applied to Cytek BioSciences Inc.

Equity curve comparison on Cytek BioSciences Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Cytek BioSciences Inc investment strategy comparison

Employed capital comparison on Cytek BioSciences Inc

Cytek BioSciences Inc investment comparison

Performance comparison on Cytek BioSciences Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -2.48% -6.0$ 242.3$ -7.75%
Momentum 1 quarter 0.94% 4.62$ 491.61$ 11.75%
Momentum 2 quarters 0% 0.0$ 0.0$ -0.0%
Non-directional 0% 0.0$ 0.0$ -0.0%
Annualized return comparison

Automatic investment

-7.75 %

Momentum 1Q

-0.0 %

Momentum 2Q

-0.0 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Cytek BioSciences Inc:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between Cytek BioSciences Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Cytek BioSciences Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Cytek BioSciences Inc
Country United States
City Fremont
Address 47215 Lakeview Boulevard
Phone 877 922 9835
Website cytekbio.com
FullTime employees 574
Industry Medical Devices
Sector Healthcare
Exchange XNAS
Ticker CTKB
Market www.nasdaq.com

Cytek BioSciences Inc ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown